Proteomics International Laboratories Ltd. (AU:PIQ) has released an update.
Proteomics International Laboratories Ltd is capitalizing on the growing direct-to-consumer healthcare trend with its novel suite of diagnostic blood tests, including PromarkerD, which has been successfully licensed in Europe and the Americas. The company is leveraging digital health advances to create cost-effective marketing opportunities, and is actively working with partners to fast-track the commercialization of its tests through specialized adoption routes. They are also exploring innovative applications of their technology, such as diagnosing plant diseases, further diversifying their portfolio of precision diagnostic services.
For further insights into AU:PIQ stock, check out TipRanks’ Stock Analysis page.